Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
Tanimura A et al. Int J Hematol. 2018 Jan 31. doi: 10.1007/s12185-018-2408-4. [Epub ahead of print].

Phase 1/2 Trial of Carfilzomib Plus High Dose Melphalan Preparative Regimen for Salvage AHCT Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
Costa LJ et al. Biol Blood Marrow Transplant. 2018 Feb 1. pii: S1083-8791(18)30053-3. doi: 10.1016/j.bbmt.2018.01.036. [Epub ahead of print].

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
Garderet L et al. Biol Blood Marrow Transplant. 2018 Feb 2. pii: S1083-8791(18)30052-1. doi: 10.1016/j.bbmt.2018.01.035. [Epub ahead of print].

Ixazomib in the management of relapsed multiple myeloma.

Touzeau C et al. Future Oncol. 2018 Feb 22. doi: 10.2217/fon-2017-0710. [Epub ahead of print].

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Krishnan A et al. Leukemia. 2018 Feb 23. doi: 10.1038/s41375-018-0038-8. [Epub ahead of print].

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV et al. Hematol Oncol. 2018 Feb 15. doi: 10.1002/hon.2499. [Epub ahead of print].

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
Dimopoulos M et al. J Clin Oncol. 2018 Feb 2:JCO2017761742. doi: 10.1200/JCO.2017.76.1742. [Epub ahead of print].

Efficacy, safety and cost of pomalidomide in relapsed and refractory multiple myeloma.
Gueneau P et al. Eur J Haematol. 2018 Feb 2. doi: 10.1111/ejh.13039. [Epub ahead of print].

Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai MyelomaForum.
Matsumura-Kimoto Y et al. Int J Hematol. 2018 Jan 29. doi: 10.1007/s12185-018-2416-4. [Epub ahead of print].

A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myelomacomplicated with diabetes mellitus – clinical significance and possible mechanisms: a case report.
Takemori N et al. J Med Case Rep. 2018 Feb 18;12(1):40. doi: 10.1186/s13256-017-1550-6.

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.
Usmani SZ et al. Exp Hematol Oncol. 2018 Feb 7;7:3. doi: 10.1186/s40164-018-0096-7. eCollection 2018.

Panobinostat and Multiple Myeloma in 2018.
Yee AJ et al. Oncologist. 2018 Feb 14. pii: theoncologist.2017-0644. doi: 10.1634/theoncologist.2017-0644. [Epub ahead of print].

The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.
Kobayashi T et al. Ann Hematol. 2018 Feb 9. doi: 10.1007/s00277-018-3270-4. [Epub ahead of print].

Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience.
Cerchione C et al. Anticancer Drugs. 2018 Feb 7. doi: 10.1097/CAD.0000000000000604. [Epub ahead of print].

Daratumumab resistance is frequent in advanced stage multiple myelomapatients irrespectively of CD38 expression, and is related to dismal prognosis.
Pick M et al. Eur J Haematol. 2018 Feb 17. doi: 10.1111/ejh.13046. [Epub ahead of print].